Navigation Links
MedImmune Announces Seven Key Promotions and New Hires

GAITHERSBURG, Md., Nov. 5 /PRNewswire/ -- MedImmune, Inc. today announced that it has made several new senior appointments across the organization. Alexander A. Zukiwski, M.D., senior vice president, clinical research; Timothy J. Hahn, Ph.D., vice president, antibody manufacturing; and Timothy J. Maines, vice president, corporate quality assurance have recently joined the company. In addition, new executive promotions include Max Donley, vice president, human resources; Jonathan Klein-Evans, J.D., vice president, intellectual property; Timothy Pearson, vice president & chief financial officer; and Paul Williams, vice president, sales operations.

"As MedImmune transitions into its new role as the global biologics unit of AstraZeneca, it is imperative to strengthen the company's leadership platform across all facets of our business. Alex, Tim Hahn and Tim Maines add an additional depth of expertise in the areas of clinical research, antibody manufacturing, and quality assurance, respectively, which are each critical to our ability to deliver new drugs to patients in need," said David M. Mott, chief executive officer and president. "The new vice presidential appointments of Max, Jonathan, Tim Pearson and Paul foster MedImmune's ability to continue to recruit and grow talent, protect our intellectual properties, manage our financial reporting obligations to AstraZeneca plc (our parent company) and serve our customers to the highest possible standards."

New Leadership

As the newest senior addition, Dr. Alexander Zukiwski joins MedImmune as senior vice president, clinical research, where he will be responsible for shaping and overseeing the company's strategy for clinical trials of its drug candidates. Prior to joining the company, Dr. Zukiwski held several roles of increasing responsibility in support of Johnson & Johnson's (J&J) medical affairs and clinical development functions at Johnson & Johnson Pharmaceutical Research & Development, LLC (J&JPRD); Centocor R&D; and Ortho Biotech, including therapeutic area head for oncology and acting head of oncology research & development. Most recently he held the position of vice president, head of clinical oncology, responsible for strategic oversight and portfolio management of therapeutic oncology, hematology and supportive care clinical development programs for J&JPRD and Centocor's oncology development group. Before joining J&J, Dr. Zukiwski served in clinical oncology positions at pharmaceutical companies such as Hoffmann-LaRoche, Glaxo Wellcome and Rhone- Poulenc Rorer. Dr. Zukiwski holds degrees in pharmacy and medicine from the University of Alberta and the University of Calgary. He conducted his post- graduate training at St. Thomas Hospital Medical Center in Akron, Ohio, and the University of Texas M.D. Anderson Cancer Center. In his new role at MedImmune, Dr. Zukiwski will report to Ed Connor, M.D., executive vice president, clinical development and chief medical officer.

Also joining MedImmune is Dr. Timothy J. Hahn, who comes to his role as vice president, antibody manufacturing, building upon his more than 15 years experience in cell culture and live virus vaccine manufacturing with Merck & Co. In his position at MedImmune, he will be responsible for the antibody manufacturing strategy, including overall operations at MedImmune's cell culture manufacturing facility currently under construction in Frederick, Maryland, as well as existing sites in Frederick and Nijmegen, Netherlands. Dr. Hahn received both his doctorate and master of science degrees in chemical engineering from Stanford University and his bachelor of science degree from Lehigh University.

Timothy J. Maines brings to MedImmune more than 20 years of pharmaceutical, medical device and biologics industry experience as a microbiologist and quality professional. In his role as vice president, corporate quality assurance, he will be responsible for fortifying world-class quality systems to improve the infrastructure of quality assurance operations in support of future growth, for ensuring the company's products meet corporate and government standards and that quality assurance activities comply with applicable regulations, and for providing enhanced expertise and guidance in interpreting government regulations and guidelines. He most recently held positions at GTC Biotherapeutics (formerly known as Genzyme Transgenics Corporation), where he served as vice president of corporate quality, and Stryker Corporation, where he was director of quality assurance. Mr. Maines holds a bachelor of science degree in biology/microbiology from Gannon University.

Management Promotions

As vice president, human resources (HR), Mr. Max Donley is responsible for providing business-integrated leadership and delivering professional tools, programs and services to optimize MedImmune's human capital investments through the HR function across all sites to drive business results. Prior to joining MedImmune in 2000 as a senior manager, he led field HR and development at Bed Bath & Beyond. Mr. Donley, a certified senior professional in human resources through the Society for Human Resource Management, holds a master and a bachelor degree in business administration from George Mason University and the University of Michigan, respectively.

Mr. Jonathan Klein-Evans now serves as vice president, intellectual property, overseeing all intellectual property issues for the company. Throughout his nearly 15 years in the field, Mr. Klein-Evans has worked on all aspects of patent law, including prosecution, litigation, opinions, interferences, oppositions and licensing. He joined MedImmune in 2002 as director, intellectual property. Previously, Mr. Klein-Evans was an in-house patent attorney at Human Genome Sciences, Inc. (HGS). Prior to his tenure at HGS, Mr. Klein-Evans worked for the law firm of Pennie & Edmonds, LLP, first as a law clerk, then a patent agent, and finally as a patent attorney over a course of six years. Mr. Klein-Evans holds a juris doctorate degree from Georgetown University Law Center; a master of science degree in biological sciences from Stanford University; and a bachelor of arts degree in biochemistry from Columbia University.

Mr. Tim Pearson was previously vice president, finance, and treasurer, and has been named chief financial officer, responsible for overseeing the company's financial and accounting obligations. Since joining MedImmune in 1998, Mr. Pearson has raised more than $1.6 billion in debt throughout the course of his tenure, and served as corporate secretary from 2000-2004. Previously, Mr. Pearson worked at Integrated Health Services, Inc., most recently as assistant treasurer; at CIGNA Insurance as treasury manager; and at First National Bank of Maryland as a commercial lending officer. He holds a master of science degree in finance from Loyola College; a bachelor of science degree in accounting from the University of Maryland; and a bachelor of science degree in business administration from the University of Delaware.

Mr. Paul Williams was promoted to vice president, sales operations, and is now responsible for overseeing market research and marketing operations as well as for managing core sales operations competencies. Prior to joining MedImmune, Mr. Williams was a senior director at Centocor, Inc., guiding trade sales, customer supply chain and channel strategy. Mr. Williams holds a bachelor of science degree in finance from Virginia Polytechnic Institute and State University in Blacksburg, Virginia.

About MedImmune

MedImmune strives to provide better medicines to patients, new medical options for physicians and rewarding careers to employees. With approximately 3,000 employees worldwide and headquarters in Maryland, MedImmune is dedicated to advancing science and medicine to help people live better lives and is wholly owned by AstraZeneca plc (LSE: AZN.L, NYSE: AZN). For more information, visit MedImmune's website at

SOURCE MedImmune, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. MedImmune Licenses Reverse Genetics Technology to Novartis for Use in Influenza Vaccine Development and Production
2. MedImmune Celebrates Opening of New Pilot Lab at Gaithersburg Headquarters
3. MedImmune Recognized by Local Volunteer Organization for Its Employees Exceptional Commitment to Community Service within Montgomery County
4. MedImmune to Present RSV Surveillance and Cost-Effectiveness Data at American Academy of Pediatrics National Conference & Exhibition
5. AstraZeneca Bolsters Its Worldwide Biologics Division Through Integration of Cambridge Antibody Technology Into MedImmune
6. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
8. Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering
9. BioLife Solutions Announces Exclusive CryoStor(TM) Supply Agreement With the New England Cryogenic Center, Inc.
10. Carrington Announces Nasdaq Communication; Prepares for Shares to Be Quoted on the OTC Bulletin Board and Pink Sheets
11. China Kangtai Cactus Biotech Files 2nd Quarter 2007 10QSB and Announces Unaudited Quarterly Results
Post Your Comments:
(Date:7/31/2020)... ... , ... R3 Stem Cell International is now offering patients the opportunity to ... total, patients may choose which extremities they would like treated. , Several studies have ... 2016). At R3 International, umbilical cord tissue is obtained from a lab with a ...
(Date:7/31/2020)... Mass. (PRWEB) , ... July 29, 2020 , ... ... highly reliable, solid-state radar transmitter systems that can be configured to drive Klystrons, ... single controller that can drive one or two switches in a push-pull configuration; ...
(Date:7/31/2020)... N.J (PRWEB) , ... July 29, 2020 , ... ... company, and Catalent, the leading global provider of advanced delivery technologies, development, and ... today announced that they have entered into a strategic partnership whereby Catalent will ...
(Date:7/31/2020)... ... July 29, 2020 , ... ... top radiation centers in 16 countries, has reached its 20th anniversary of worldwide ... in routine use at top universities including University of Pennsylvania, University of Michigan, ...
Breaking Biology Technology:
(Date:8/26/2020)... ... August 25, 2020 , ... ... in partnership with Essex Bio-Technology, a bio-pharmaceutical company specializing in Ophthalmology and ... study of SkQ1 ophthalmic solution in patients with moderate to severe Dry ...
(Date:8/21/2020)... ... August 18, 2020 , ... ... therapy, today announced that the U.S. Food and Drug Administration (FDA) has approved ... asset, SBI-101, for the treatment of severe COVID-19. Approval of this IND allows ...
(Date:8/12/2020)... ... 2020 , ... Both Roche, based in Basel, Switzerland, and ... with Housey Pharma’s HMI subsidiary to gain access to its core-enabling technology for ... Development spending in excess of US $10 billion. , Scientists at Housey Pharma ...
Breaking Biology News(10 mins):